Roche presents restistance-breaking antibiotic
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2168 entries already.
Entries by Thomas Gabrielczyk
Alfasigma SpA signs €170m deal with Galapagos NV
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Metrion Biosciences closes £3.7m equity financing
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.
French parliamentarians against cell-based meat
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
Vandria SA bags CHF18m in Series A financing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
Cell-free protein synthesis systems
Cell-free protein synthesis (CFPS) systems allow rapid protein production in vitro without the need for living cells, offering distinct advantages.
Antabio SAS raises €25 m in Series B financing
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
Production process for cell-based coffee published
Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.